FAQ

Parathormone (human recombinant)

Known as: parathyroid hormone (1-84) human recombinant, rhPTH, rhPTH(1-84) 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2000-2017
0520002017

Related topics

Related topics

1 relation

Broader (1)

Recombinant parathyroid hormone

Related mentions per year

Related mentions per year

1945-2018
19401960198020002020
Parathormone (human recombinant)
Recombinant parathyroid hormone

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
PTH(1-84) replacement therapy in hypoparathyroidism: a randomized controlled trial on pharmacokinetic and dynamic effects after 6 months of treatment.
Untreated, hypoparathyroidism (hypoPT) is a state of hypocalcemia with inappropriately low plasma parathyroid hormone (PTH… (More)
Is this relevant?
2013
2013
Comparison of parathyroid hormone (1-34) and elcatonin in postmenopausal women with osteoporosis: an 18-month randomized, multicenter controlled trial in China.
BACKGROUND Recombinant human parathyroid hormone (1-34) (rhPTH (1-34)) is the first agent in a unique class of anabolic therapies… (More)
Is this relevant?
2013
2013
Evaluation of the efficacy, safety and pharmacokinetic profile of oral recombinant human parathyroid hormone [rhPTH(1-31)NH(2)] in postmenopausal women with osteoporosis.
CONTEXT Treatment of osteoporosis with subcutaneous (SC) injections of rhPTH(1-34) or rhPTH(1-84) is associated with significant… (More)
Is this relevant?
2011
2011
Teriparatide vs. Alendronate as a treatment for osteoporosis: Changes in biochemical markers of bone turnover, BMD and quality of life
BACKGROUND We studied the use of teriparatide in postmenopausal women with severe osteoporosis. MATERIAL/METHODS Two groups (A… (More)
  • table 1
  • figure 1
  • figure 3
  • figure 2
  • figure 4
Is this relevant?
2011
2011
Teriparatide [rhPTH (1-34)], but not strontium ranelate, demonstrated bone anabolic efficacy in mature, osteopenic, ovariectomized rats.
We compared teriparatide (TPTD) and strontium ranelate (SR) efficacy on bone formation activity in a mature rat model of estrogen… (More)
Is this relevant?
2009
2009
Histomorphometric changes by teriparatide in alendronate-pretreated women with osteoporosis
The level of increased bone formation after 24 months of treatment with teriparatide (rhPTH (1–34), TPTD) is similar in patients… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
2008
2008
Endogenous intact PTH is suppressed during Teriparatide (rhPTH 1-34) administration in postmenopausal women with established osteoporosis.
INTRODUCTION Teriparatide (recombinant human PTH 1-34/TPTD) is an osteoanabolic agent available for osteoporosis treatment. The… (More)
Is this relevant?
2007
2007
Patient willingness to take teriparatide.
OBJECTIVE Teriparatide [rhPTH (1-34)] is an effective treatment for osteoporosis administered by daily subcutaneous injection… (More)
Is this relevant?
2006
2006
Reduction in the risk of developing back pain persists at least 30 months after discontinuation of teriparatide treatment: a meta-analysis
Teriparatide [rhPTH (1–34)] reduces fracture risk, and in a published meta-analysis of clinical trials, teriparatide-treated… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
Is this relevant?
2005
2005
Effects of teriparatide [rhPTH (1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women.
INTRODUCTION We evaluated effects of teriparatide (rDNA origin) injection [teriparatide, rhPTH (1-34), TPTD] on hip structure… (More)
Is this relevant?